Europe has traditionally been a world leader in the development of Advanced Therapies. However, since the introduction of the EMA’s Advanced Therapy Medicinal Products (ATMP) designation in 2007, half of the products approved have failed in commercialisation and have been withdrawn from the EU market.

This webinar discussed the mounting challenges to Europe’s ATMP sector and offer tangible suggestions as to what Europe needs to do to ensure it can develop needed new Advanced Therapies and bring them to patients.